Our Equity Story

A unique immunomodulatory enzyme technology

Imlifidase is a unique IgG antibody-cleaving enzyme with a rapid onset of action and high specificity for inactivation of IgG in patients with rare immunologic diseases

Controlling the full value chain from early discovery through commercialization to maximize the value creation and capture

Preparing for potential launch of imlifidase under conditional approval in core European markets starting in H2 2020. MAA is currently under review by EMA
Imlifidase to be launched through Hansa´s own medical and commercial organization, while the company is expected to pursue a partnership strategy outside core markets
In the US a clear regulatory path has been agreed with the FDA that support potential submission of a BLA in 2023 under the accelerated approval pathway
Broad technology protection with patent coverage throughout 2035 in key markets and orphan drug designation in both the US/EU in our lead indications

Advancing our pipeline with three phase 2 programs in transplantation and acute autoimmune diseases.
New set of modified enzymes under development (NiceR program) for repeat dosing; potentially enabling treatment in relapsing diseases and oncology
Exploring potential combination therapies in oncology with IgG-modulating enzymes and gene therapy in patients with neutralizing antibodies through partnerships